BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16047348)

  • 1. Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL.
    Bay A; Oner AF; Cesur Y; Dogan M; Etlik O; Sanli F
    Pediatr Blood Cancer; 2006 Sep; 47(3):330-1. PubMed ID: 16047348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
    Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
    Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
    Melachuri S; Gandrud L; Bostrom B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypoglycemic seizures in a child receiving 6-mercaptopurine.
    El-Bitar MK; Muwakkit SA; Dabbagh O
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):e75-6. PubMed ID: 21343747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia.
    Halonen P; Salo MK; Mäkipernaa A
    J Pediatr; 2001 Mar; 138(3):428-31. PubMed ID: 11241057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.
    Visavachaipan N; Aledo A; Franklin BH; Brar PC
    Diabetes Technol Ther; 2013 Jan; 15(1):97-100. PubMed ID: 23145966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia.
    Merino JM; Casanova F; Sáez-Royuela F; Velasco A; González JB
    Pediatr Hematol Oncol; 2000; 17(5):429-31. PubMed ID: 10914056
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction in bioavailability of 6-mercaptopurine on simultaneous administration with cow's milk.
    Sofianou-Katsoulis A; Khakoo G; Kaczmarski R
    Pediatr Hematol Oncol; 2006 Sep; 23(6):485-7. PubMed ID: 16849279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
    Taylor JA; Winter L; Geyer LJ; Hawkins DS
    Cancer; 2006 Sep; 107(6):1400-6. PubMed ID: 16909415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of obesity in paediatric leukaemia treatment: it is not just size that matters.
    Tolbert J; Kearns GL
    Arch Dis Child; 2015 Jan; 100(1):101-5. PubMed ID: 25336436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.
    Mohnike K; Blankenstein O; Pfuetzner A; Pötzsch S; Schober E; Steiner S; Hardy OT; Grimberg A; van Waarde WM
    Horm Res; 2008; 70(1):59-64. PubMed ID: 18493152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
    Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
    Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
    Dixit A; Chatterjee T; Mishra P; Kannan M; Choudhry DR; Mahapatra M; Choudhry VP; Saxena R
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):292-8. PubMed ID: 17636191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.